Overview

AZD3355 Dose-escalation Study in Healthy Males

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inactive substance"). Safety and tolerability variables will be closely monitored throughout the study.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Lesogaberan